A new composite model including metabolic syndrome, alanine aminotransferase and cytokeratin-18 for the diagnosis of non-alcoholic steatohepatitis in morbidly obese patients

Alimentary Pharmacology and Therapeutics

Volumn 32, Issue 11-12, 2010, Pages 1315-1322

  Anty, R ^a,b,c   Iannelli, A ^a,b,c   Patouraux, S ^a,b   Bonnafous, S ^a,b,c   Lavallard, V J ^a,b,c   Senni Buratti, M ^b   Ben Amor, I ^b   Staccini Myx, A ^b   Saint Paul, M C ^a,b   Berthier, F ^d   Huet, P M ^b   Le Marchand Brustel, Y ^a,b,c   Gugenheim, J ^a,b,c   Gual, P ^a,b,c   Tran, A ^a,b,c  

^a INSERM   (France)

^b UNIVERSITY HOSPITAL OF NICE   (France)

^c UNIVERSITÉ CÔTE D'AZUR   (France)

^d CENTRE HOSPITALIER PRINCESSE GRACE   (Monaco)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; CASPASE 3; CYTOKERATIN 18;

ADULT; ARTICLE; DIAGNOSTIC ACCURACY; DISEASE SEVERITY; FEMALE; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; NONALCOHOLIC FATTY LIVER; OBESITY; PRIORITY JOURNAL; SCORING SYSTEM; SENSITIVITY AND SPECIFICITY;

ADULT; ALANINE TRANSAMINASE; BODY MASS INDEX; CASE-CONTROL STUDIES; FATTY LIVER; FEMALE; HUMANS; KERATIN-18; LIVER FUNCTION TESTS; MALE; METABOLIC SYNDROME X; MIDDLE AGED; MODELS, BIOLOGICAL; OBESITY, MORBID; PREDICTIVE VALUE OF TESTS; RISK FACTORS; STATISTICS AS TOPIC;

EID: 78449286054     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/j.1365-2036.2010.04480.x     Document Type: Article

References (34)

1. Torres DM, Harrison SA,. Diagnosis and therapy of nonalcoholic steatohepatitis. Gastroenterology 2008; 134: 1682 - 98.
2. Ekstedt M, Franzen LE, Mathiesen UL, et al. Long-term follow-up of patients with NAFLD and elevated liver enzymes. Hepatology 2006; 44: 865 - 73.
3. Adams LA, Lymp JF, St Sauver J, et al. The natural history of nonalcoholic fatty liver disease: a population-based cohort study. Gastroenterology 2005; 129: 113 - 21.
4. Machado M, Marques-Vidal P, Cortez-Pinto H,. Hepatic histology in obese patients undergoing bariatric surgery. J Hepatol 2006; 45: 600 - 6.
5. Huang HL, Lin WY, Lee LT, Wang HH, Lee WJ, Huang KC,. Metabolic syndrome is related to nonalcoholic steatohepatitis in severely obese subjects. Obes Surg 2007; 17: 1457 - 63.
6. Maher JJ, Leon P, Ryan JC,. Beyond insulin resistance: innate immunity in nonalcoholic steatohepatitis. Hepatology 2008; 48: 670 - 8.
7. Greenfield V, Cheung O, Sanyal AJ,. Recent advances in nonalcholic fatty liver disease. Curr Opin Gastroenterol 2008; 24: 320 - 7.
8. Alberti KG, Zimmet P, Shaw J,. Metabolic syndrome - a new world-wide definition. A Consensus Statement from the International Diabetes Federation. Diabet Med 2006; 23: 469 - 80.
9. Lee WJ, Huang MT, Wang W, Lin CM, Chen TC, Lai IR,. Effects of obesity surgery on the metabolic syndrome. Arch Surg 2004; 139: 1088 - 92.
10. Despres JP, Lemieux I,. Abdominal obesity and metabolic syndrome. Nature 2006; 444: 881 - 7.
11. Feldstein AE, Canbay A, Angulo P, et al. Hepatocyte apoptosis and fas expression are prominent features of human nonalcoholic steatohepatitis. Gastroenterology 2003; 125: 437 - 43.
12. Ratziu V, Charlotte F, Heurtier A, et al. Sampling variability of liver biopsy in nonalcoholic fatty liver disease. Gastroenterology 2005; 128: 1898 - 906.
13. Merriman RB, Ferrell LD, Patti MG, et al. Correlation of paired liver biopsies in morbidly obese patients with suspected nonalcoholic fatty liver disease. Hepatology 2006; 44: 874 - 80.
14. Saadeh S, Younossi ZM, Remer EM, et al. The utility of radiological imaging in nonalcoholic fatty liver disease. Gastroenterology 2002; 123: 745 - 50.
15. Palekar NA, Naus R, Larson SP, Ward J, Harrison SA,. Clinical model for distinguishing nonalcoholic steatohepatitis from simple steatosis in patients with nonalcoholic fatty liver disease. Liver Int 2006; 26: 151 - 6.
16. Campos GM, Bambha K, Vittinghoff E, et al. A clinical scoring system for predicting nonalcoholic steatohepatitis in morbidly obese patients. Hepatology 2008; 47: 1916 - 23.
17. Dixon JB, Bhathal PS, OBrien PE,. Nonalcoholic fatty liver disease: predictors of nonalcoholic steatohepatitis and liver fibrosis in the severely obese. Gastroenterology 2001; 121: 91 - 100.
18. Gholam PM, Flancbaum L, Machan JT, Charney DA, Kotler DP,. Nonalcoholic fatty liver disease in severely obese subjects. Am J Gastroenterol 2007; 102: 399 - 408.
19. Poynard T, Ratziu V, Charlotte F, et al. Diagnostic value of biochemical markers (NashTest) for the prediction of non alcoholo steato hepatitis in patients with non-alcoholic fatty liver disease. BMC Gastroenterol 2006; 6: 34.
20. Feldstein AE, Wieckowska A, Lopez AR, Liu YC, Zein NN, McCullough AJ,. Cytokeratin-18 fragment levels as noninvasive biomarkers for nonalcoholic steatohepatitis: a multicenter validation study. Hepatology 2009; 50: 1072 - 8.
21. Diab DL, Yerian L, Schauer P, et al. Cytokeratin 18 fragment levels as a noninvasive biomarker for nonalcoholic steatohepatitis in bariatric surgery patients. Clin Gastroenterol Hepatol 2008; 6: 1249 - 54.
22. Younossi ZM, Jarrar M, Nugent C, et al. A novel diagnostic biomarker panel for obesity-related nonalcoholic steatohepatitis (NASH). Obes Surg 2008; 18: 1430 - 7.
23. Yilmaz Y,. Systematic review: caspase-cleaved fragments of cytokeratin 18 - the promises and challenges of a biomarker for chronic liver disease. Aliment Pharmacol Ther 2009; 30: 1103 - 9.
24. NIH conference. Gastrointestinal surgery for severe obesity. Consensus Development Conference Panel. Ann Intern Med 1991; 115: 956 - 61.
25. Wallace T, Matthews D,. The assessment of insulin resistance in man. Diabet Med 2002; 19: 527 - 34.
26. Kleiner DE, Brunt EM, Van Natta M, et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology 2005; 41: 1313 - 21.
27. Wieckowska A, Zein NN, Yerian LM, Lopez AR, McCullough AJ, Feldstein AE,. In vivo assessment of liver cell apoptosis as a novel biomarker of disease severity in nonalcoholic fatty liver disease. Hepatology 2006; 44: 27 - 33.
28. Goessling W, Massaro JM, Vasan RS, DAgostino RB Sr, Ellison RC, Fox CS,. Aminotransferase levels and 20-year risk of metabolic syndrome, diabetes, and cardiovascular disease. Gastroenterology 2008; 135: 1935 - 44.
29. Mofrad P, Contos MJ, Haque M, et al. Clinical and histologic spectrum of nonalcoholic fatty liver disease associated with normal ALT values. Hepatology 2003; 37: 1286 - 92.
30. Kunde SS, Lazenby AJ, Clements RH, Abrams GA,. Spectrum of NAFLD and diagnostic implications of the proposed new normal range for serum ALT in obese women. Hepatology 2005; 42: 650 - 6.
31. Fracanzani AL, Valenti L, Bugianesi E, et al. Risk of severe liver disease in nonalcoholic fatty liver disease with normal aminotransferase levels: a role for insulin resistance and diabetes. Hepatology 2008; 48: 792 - 8.
32. Wong VW, Wong GL, Choi PC, et al. Disease progression of non-alcoholic fatty liver disease: a prospective study with paired liver biopsies at 3 years. Gut 2010; 59: 969 - 74.
33. Ulitsky A, Ananthakrishnan AN, Komorowski R, et al. A noninvasive clinical scoring model predicts risk of nonalcoholic steatohepatitis in morbidly obese patients. Obes Surg 2010; 20: 685 - 91.
34. Munteanu M, Ratziu V, Morra R, Messous D, Imbert-Bismut F, Poynard T,. Noninvasive biomarkers for the screening of fibrosis, steatosis and steatohepatitis in patients with metabolic risk factors: FibroTest-FibroMax experience. J Gastrointestin Liver Dis 2008; 17: 187 - 91.